Abvc Biopharma (ABVC) Net Cash Flow (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Net Cash Flow came in at -$119735.0 in Q2 2026, down 111.59% on a YoY basis from $1.0 million in Q2 2025, and up 89.93% quarter-over-quarter from -$1.2 million in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Net Cash Flow (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Net Cash Flow for 17 consecutive years, with -$119735.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Cash Flow fell 111.59% year-over-year to -$119735.0; the trailing twelve-month figure through Jun 2026 stood at -$1.1 million (down 293.7% YoY), and the FY2025 full-year result was $442906.0, up 158.07% from the prior year.
- Net Cash Flow advanced to -$119735.0 in Q2 2026 per ABVC's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $1.0 million in Q2 2025 and bottomed at -$3.5 million in Q2 2022.
- Historically, Net Cash Flow has averaged -$499470.8 across 5 years, with a median of -$178802.0 in 2023.
- The widest YoY moves for Net Cash Flow: up 225.8% in 2025, down 1257.09% in 2025.
- Over 5 years, Net Cash Flow stood at -$797857.0 in 2022, then jumped by 70.19% to -$237869.0 in 2023, then slumped by 54.0% to -$366312.0 in 2024, then surged by 225.8% to $460828.0 in 2025, then slumped by 125.98% to -$119735.0 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$119735.0, -$1.2 million, and $460828.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | -119,735.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -119,735.00 |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | 460,828.00 |
| Sep 30, 2025 | -274,219.00 |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | -111,077.00 |
| Dec 31, 2024 | -366,312.00 |
| Sep 30, 2024 | 23,699.00 |
| Jun 30, 2024 | 590,731.00 |
| Mar 31, 2024 | -31,669.00 |
| Dec 31, 2023 | -237,869.00 |
| Sep 30, 2023 | 223,831.00 |
| Jun 30, 2023 | -931,414.00 |
| Mar 31, 2023 | 708,954.00 |
| Dec 31, 2022 | -797,857.00 |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | -3.09 Mn |
| Dec 31, 2021 | 2.16 Mn |
| Sep 30, 2021 | 2.79 Mn |